New collaboration for Kite and Sangamo

0

A worldwide collaboration focusing on Sangamo’s zinc finger nuclease (ZFN) technology platform has been signed with Kite, part of Gilead. ZFN technology will be used to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Under the terms of the agreement, Sangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, aggregated across 10 or more products utilizing Sangamo’s technology.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here